AZD7762 is a selective checkpoint kinases 1 and 2 inhibitor, and a previous meta-analysis suggested an association between checkpoint kinase 2 mutation and increased risk of BC (Liang et al., 2018; Ma et al., 2012; Park et al., 2016). This evidence concerns the gene CHEK2 and breast cancer.